EVERJOY HEALTH(002162)

Search documents
悦心健康(002162) - 2021 Q1 - 季度财报
2021-04-14 16:00
Financial Performance - The company's revenue for Q1 2021 was ¥208,808,508.79, representing a 71.90% increase compared to ¥121,471,485.59 in the same period last year[8]. - The net profit attributable to shareholders was -¥11,532,792.93, an improvement of 39.55% from -¥19,076,892.88 year-on-year[8]. - The net cash flow from operating activities was -¥34,827,113.90, showing a 48.10% improvement compared to -¥67,104,046.16 in the previous year[8]. - Revenue for Q1 2021 reached RMB 208.81 million, a 71.90% increase compared to RMB 121.47 million in Q1 2020[18]. - Operating costs increased to RMB 150.25 million, reflecting a 91.09% rise from RMB 78.63 million in the same period last year[18]. - The company reported a net loss attributable to shareholders of RMB 11.53 million, a 39.55% improvement from a loss of RMB 19.08 million in the previous year[18]. - Net loss for Q1 2021 was CNY 11,921,556.76, compared to a net loss of CNY 20,710,620.47 in the same period last year, representing a 42.5% improvement[45]. - Total comprehensive income for the first quarter was CNY 2,489,195.21, compared to CNY 2,428,861.30 in the previous year, reflecting a slight increase[50]. Cash Flow and Liquidity - The cash and cash equivalents decreased by 41.77% to ¥130,729,579.54, primarily due to payments to suppliers and repayment of bank loans[16]. - Cash inflow from operating activities totaled CNY 268,530,641.59, significantly up from CNY 129,808,069.49 in the same period last year, indicating strong operational performance[53]. - Net cash flow from operating activities was negative CNY 34,827,113.90, an improvement from negative CNY 67,104,046.16 in the previous year, showing reduced cash outflow[53]. - The ending cash and cash equivalents balance was CNY 88,549,436.08, down from CNY 136,173,705.14, indicating a decrease in liquidity[54]. - Total cash outflow for operating activities was CNY 160,904,466.03, up from CNY 115,045,443.15, indicating increased operational costs[55]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,472,343,154.33, a decrease of 1.17% from ¥2,501,558,406.84 at the end of the previous year[8]. - Total current assets decreased to CNY 883,739,875.73 from CNY 961,174,100.34 as of December 31, 2020, representing a decline of approximately 8.06%[35]. - Total liabilities decreased to CNY 1,437,882,348.25 from CNY 1,455,162,438.53, a decline of approximately 1.18%[37]. - The company's total equity as of March 31, 2021, was CNY 1,034,460,806.08, down from CNY 1,046,395,968.31, indicating a decrease of about 1.14%[38]. - The total assets as of March 31, 2021, were CNY 2,472,343,154.33, down from CNY 2,501,558,406.84, reflecting a decrease of about 1.17%[38]. - Total liabilities amounted to CNY 1,455,162,438.53, with a total adjustment of CNY 57,391,998.71[60]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 71,020[12]. - CIMIC Industrial Inc. held 46.83% of the shares, making it the largest shareholder[12]. Research and Development - R&D expenses rose to RMB 2.35 million, marking a 54.36% increase from RMB 1.52 million year-over-year[18]. - Research and development expenses rose to CNY 2,353,669.55 from CNY 1,524,776.80, indicating a focus on innovation[44]. Investment Activities - Investment income decreased by 43.18% to RMB 0.81 million, down from RMB 1.43 million in the previous year[18]. - The company reported investment income of CNY 814,727.64, down from CNY 1,433,999.17 year-on-year[44]. - The company received CNY 33,000,000.00 from investment activities, down from CNY 60,000,000.00, reflecting a decrease in new investments[57]. Accounting and Reporting Changes - The company plans to adjust its financial statements in accordance with new leasing standards starting in 2021, indicating a strategic shift in accounting practices[58]. - The company recognized a lease liability of CNY 45,967,377.33 and a right-of-use asset of CNY 58,780,316.46 due to the new leasing standards[62]. - The company did not audit the first quarter report[67]. - The company has not opted to adjust prior comparative data under the new leasing standard[67].
悦心健康(002162) - 2020 Q4 - 年度财报
2021-03-26 16:00
Financial Performance - The company's operating revenue for 2020 was CNY 1,194,703,084.49, representing a 2.44% increase compared to CNY 1,166,237,543.76 in 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 57,195,036.74, a significant increase of 51.02% from CNY 37,872,539.05 in 2019[17]. - The net profit after deducting non-recurring gains and losses was CNY 35,167,176.89, which is an 86.12% increase compared to CNY 18,895,063.89 in 2019[17]. - The net cash flow from operating activities for 2020 was CNY 152,455,604.70, up 15.37% from CNY 132,140,708.26 in 2019[17]. - Basic earnings per share for 2020 were CNY 0.0670, reflecting a 50.90% increase from CNY 0.0444 in 2019[17]. - Total revenue for the year was approximately CNY 1.17 billion, with a quarterly breakdown of CNY 121.47 million in Q1, CNY 329.38 million in Q2, CNY 385.87 million in Q3, and CNY 357.98 million in Q4[21]. - The net profit attributable to shareholders was CNY -19.08 million in Q1, CNY 42.49 million in Q2, CNY 29.90 million in Q3, and CNY 3.89 million in Q4, indicating a significant recovery in profitability in the second and third quarters[21]. - Total revenue for 2020 reached CNY 1.195 billion, a year-on-year increase of 2.44%, with stylish health building materials accounting for 86.49% of total revenue[42]. - Net profit attributable to shareholders increased by 51.02% year-on-year, reaching CNY 57.20 million[42]. - The company’s cash flow from operating activities reached CNY 152 million, reflecting a year-on-year growth of 15.37%[42]. Assets and Liabilities - Total assets at the end of 2020 amounted to CNY 2,501,558,406.84, a 6.89% increase from CNY 2,340,351,166.84 at the end of 2019[17]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,034,970,311.17, which is a 5.85% increase from CNY 977,740,693.11 at the end of 2019[17]. - The company’s debt totaled CNY 1,312.66 billion at the end of 2020, reflecting a year-on-year increase of 12.97%[50]. - The company reported a net receivables of CNY 252.79 billion, a year-on-year increase of 39.37%, indicating a need for improved receivables management[50]. - The company’s short-term borrowings decreased to ¥410,217,587.18, down 5.21% from ¥505,648,774.19 at the beginning of the year[87]. Investments and Acquisitions - Long-term equity investments increased by CNY 17.90 million, a growth of 38.59% compared to the beginning of the year, mainly due to the investment in Jiangsu Anyi Health Management Group Co., Ltd.[33]. - The company has initiated a training center for elderly care professionals, offering courses for caregivers and plans to expand training offerings to include nursery and housekeeping services[49]. - The company plans to continue external acquisitions to develop its health industry, requiring effective management and supervision of acquisition targets[110]. Research and Development - Research and development expenses increased by 16.35% to CNY 50 million, reflecting higher investments in new product and technology development for tiles[60]. - The company has maintained a workforce of 235 R&D personnel, a decrease of 4.08% from 245 in 2019, with R&D personnel accounting for 19.53% of the total workforce[78]. - The company has developed a series of negative ion health materials, including negative ion health boards and coatings, which have received multiple national patents and certifications[45]. Healthcare Services - The company’s healthcare services focus on integrated medical services, with investments in multiple healthcare facilities, including hospitals and clinics[29]. - The company’s healthcare services are expanding through both organic growth and acquisitions, focusing on specialized hospitals and women's health services[29]. - The company has focused on women's healthcare by divesting from inefficient medical projects, enhancing its core medical services for female clients, including obstetrics and cosmetic medical services[46]. Environmental and Social Responsibility - The company adheres to environmental protection standards and ensures zero discharge of industrial wastewater[167]. - Jiangxi Smick Ceramics Co., Ltd. achieved a reduction in actual emissions by approximately 58.8% in 2020, with particulate matter emissions at 7.79 mg/Nm³, SO2 at 14.69 mg/Nm³, and NOX at 42.44 mg/Nm³[171]. - The company has implemented a comprehensive environmental management system, including quality, environmental, energy, and occupational health safety management[170]. Shareholder Information - The total number of shareholders at the end of the reporting period was 58,120, an increase from 54,962 at the end of the previous month[188]. - CIMIC INDUSTRIAL INC. holds 46.83% of the shares, amounting to 399,795,802 shares, making it the largest shareholder[189]. - The controlling shareholder, CIMIC INDUSTRIAL INC., is a foreign entity established on September 24, 1997, primarily engaged in investment business[190]. - There were no changes in the controlling shareholder during the reporting period[191]. Future Outlook - The company expects significant growth in the construction ceramics industry, driven by domestic market demand and urban renovation projects, with a focus on personalized products[99]. - The healthcare market in China is projected to experience substantial growth, supported by favorable policies and increasing demand for private medical services[101]. - The aging population in China presents a growing market for elderly care services, with over 40 million elderly individuals experiencing varying degrees of disability[102].
悦心健康(002162) - 2020 Q3 - 季度财报
2020-10-29 16:00
Financial Performance - Net profit attributable to shareholders rose by 51.76% to CNY 29,895,788.51 for the current period[7] - Operating revenue for the current period was CNY 385,874,472.69, an increase of 11.03% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 61.10% to CNY 30,851,077.94[7] - Basic earnings per share rose by 51.52% to CNY 0.0350[7] - Total operating revenue for Q3 2020 was CNY 385,874,472.69, an increase from CNY 347,549,996.90 in the previous period[45] - Net profit for Q3 2020 reached CNY 24,801,201.47, compared to CNY 19,446,690.42 in the same period last year, representing a growth of approximately 27.5%[47] - The net profit for the current period is ¥854,245.36, significantly lower than ¥10,195,938.84 in the previous period, reflecting a challenging market environment[51] - The net profit attributable to the parent company is ¥53,305,548.64, up from ¥34,217,985.46, indicating improved profitability[56] Assets and Liabilities - Total assets increased by 10.23% to CNY 2,579,684,756.89 compared to the end of the previous year[7] - The company's total assets decreased by 100% in trading financial assets, reflecting the redemption of all financial products during the reporting period[15] - The total liabilities increased significantly, with current liabilities due within one year rising by 475.13% to RMB 98,330,183.38, largely from financing arrangements[16] - The total liabilities increased to CNY 1,518,067,027.15 from CNY 1,347,767,676.46, representing a rise of approximately 12.6%[39] - The company's total assets amounted to CNY 2,645,244,404.70, slightly up from CNY 2,640,592,119.01[43] - Total liabilities were CNY 1,230,675,108.40, remaining stable compared to CNY 1,230,675,792.81 in the previous period[43] - The company's equity increased to CNY 1,414,569,296.30 from CNY 1,409,916,326.20, reflecting a growth of about 0.4%[43] Cash Flow - The net cash flow from operating activities increased by 104.65% to CNY 59,380,526.05[7] - Cash flow from operating activities decreased by 29.86% to RMB 49,762,386.55, primarily due to cash collection being affected by project progress[25] - The net cash flow from financing activities improved by 85.10%, amounting to a net outflow of RMB 22,340,649.11, due to increased capital contributions from minority shareholders[26] - Cash flow from operating activities generated $49.76 million, down 29.9% from $70.95 million in the previous period[63] - Cash flow from investing activities resulted in a net outflow of $57.83 million, compared to a smaller outflow of $8.84 million last year[63] - Cash inflow from financing activities increased to ¥250,813,495.95 from ¥168,589,605.52, leading to a net cash flow from financing activities of ¥34,139,541.43[67] Shareholder Information - The total number of shareholders at the end of the reporting period was 49,424[11] - CIMIC Industrial Inc. held the largest share, with a 46.83% stake, totaling 399,795,802 shares[11] Research and Development - Research and development expenses rose by 37.62% to RMB 3,284,997.15 in Q3 2020, reflecting increased investment in innovation[20] - Research and development expenses for the quarter were CNY 3,284,997.15, compared to CNY 2,386,997.43 in the same period last year, indicating an increase of approximately 37.6%[46] - Research and development expenses increased to ¥599,280.13 from ¥449,178.12, highlighting the company's commitment to innovation[49] Government Support - The company received government subsidies totaling CNY 6,437,866.01, primarily from local government support[8] Other Financial Metrics - The weighted average return on equity increased to 3.01%, up from 0.92%[7] - The company reported a significant increase in construction in progress, up 305.88% to RMB 111,521,792.66, attributed to new investments in subsidiaries[16] - The company experienced a 285.54% increase in credit impairment losses, amounting to RMB 10,958,781.39, due to changes in accounting estimates for receivables[21] - The company's interest income increased by 80.25% to RMB 461,877.46 in Q3 2020, driven by higher bank acceptance bill deposits[20] - The company reported investment income of CNY 963,942.38, down from CNY 1,887,896.42 year-over-year[46]
悦心健康(002162) - 2020 Q2 - 季度财报
2020-08-14 16:00
Financial Performance - The company's operating revenue for the first half of 2020 was CNY 450,851,208.09, a decrease of 10.31% compared to CNY 502,663,499.02 in the same period last year[17]. - Net profit attributable to shareholders increased by 61.25% to CNY 23,409,760.13, up from CNY 14,518,091.73 in the previous year[17]. - The net profit after deducting non-recurring gains and losses surged by 143.52% to CNY 11,456,322.24, compared to CNY 4,704,490.71 in the same period last year[17]. - The company achieved total revenue of CNY 451 million in the first half of 2020, a decrease of 10% year-on-year, with the building materials segment accounting for 82.37% of total revenue[43]. - The net profit attributable to shareholders increased by 61.25% year-on-year to CNY 23.41 million, while total profit rose by 34.06% to CNY 22.84 million[43]. - The average gross margin for the tile business was 31.1%, a decrease of 1.18% year-on-year, with tile sales volume down by 8.24%[43]. - The company's operating revenue for the reporting period was ¥450,851,208.09, a decrease of 10.31% compared to ¥502,663,499.02 in the same period last year, primarily due to the impact of the COVID-19 pandemic on construction materials and healthcare revenue[53]. - Operating costs decreased by 7.79% to ¥300,008,262.99 from ¥325,342,933.75, reflecting the reduction in operating revenue[53]. - The company reported a significant increase in medical service revenue, which was significantly impacted by the pandemic, with a 48.17% year-on-year decrease in revenue from the US-based reproductive center[43]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 2,385,561,615.57, reflecting a 1.93% increase from CNY 2,340,351,166.84 at the end of the previous year[17]. - The net assets attributable to shareholders rose by 2.40% to CNY 1,001,159,067.12, compared to CNY 977,740,693.11 at the end of the previous year[17]. - The company's total liabilities stood at CNY 1,363,761,128.52, up from CNY 1,347,767,676.46, marking an increase of about 1.03%[156]. - The company's total liabilities decreased to CNY 1.18 billion from CNY 1.23 billion at the end of 2019, a reduction of 4.2%[161]. - The company's total equity at the end of the reporting period is 1,388,721,900 CNY, showing an increase from the previous period's 1,358,171,400 CNY, representing a growth of approximately 2.2%[188]. Cash Flow - The net cash flow from operating activities was negative at CNY -9,618,139.50, a decline of 122.94% compared to CNY 41,931,718.70 in the previous year[17]. - The company's cash flow from operating activities was negative CNY 9.62 million, a decrease of CNY 51.55 million year-on-year, primarily due to extended payment terms with strategic engineering clients[44]. - The company reported a net cash decrease of ¥65,532,739.66, which is a 107.13% increase in cash outflow compared to the previous year[55]. - The company's operating cash flow for the first half of 2020 was negative at CNY -9,618,139.50, compared to a positive cash flow of CNY 41,931,718.70 in the same period of 2019[172]. - The total cash inflow from operating activities was CNY 449,858,459.06, down from CNY 519,914,232.16 in the first half of 2019[172]. Investments and R&D - Research and development investment increased significantly by 123.75% to ¥19,449,266.42, driven by the development of new products such as marble and polished tiles[54]. - The company invested CNY 4.53 million in R&D expenses, an increase from CNY 3.94 million in the same period last year, indicating a focus on innovation[162]. - The company has expanded its medical services through investments in multiple healthcare facilities, including the US-based Daystar Fertility Center[31]. - The company has initiated a project in Suqian County for a comprehensive health management center, with the medical rehabilitation project starting operations in June 2020[49]. Market and Product Development - The company reported a significant increase in construction materials sales, driven by the introduction of new products and strategic partnerships, with a 36.41% increase in accounts receivable compared to the beginning of the year[35]. - The company launched a new 1200*2400mm large-format slab in 2019, enhancing its product offerings in home decoration applications[26]. - The company’s brand "Simeike" has established a strong market presence in the high-end ceramic tile sector, reflecting nearly 30 years of industry experience[39]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[183]. Environmental and Social Responsibility - The company has implemented a comprehensive environmental management system, ensuring compliance with national pollution discharge standards and achieving zero discharge of industrial wastewater[115]. - The company reported a total environmental protection expenditure of approximately 1.7874 million yuan in the first half of 2020, including solid waste disposal fees, environmental taxes, and maintenance costs for environmental facilities[120]. - The company has adopted online monitoring systems for real-time tracking of emissions, integrated with local environmental monitoring platforms[117]. - The company has established an emergency response plan for environmental incidents, which has been reviewed and filed with the local environmental protection bureau[119]. Shareholder Information - The company reported a total of 853,775,000 shares outstanding, with 99.91% being unrestricted shares[130]. - The number of shareholders holding ordinary shares reached 50,734 by the end of the reporting period[134]. - CIMIC INDUSTRIAL INC. holds 46.83% of the total shares, amounting to 399,795,802 shares[134]. - DIGITAL PACIFIC INC. owns 7.22% of the shares, totaling 61,607,356 shares[134]. Corporate Governance - The company has not engaged in any significant equity or non-equity investments during the reporting period[69]. - The company has no significant litigation or arbitration matters during the reporting period[90]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[138]. - The company has not reported any significant changes in its ownership structure during the current reporting period[191].
悦心健康(002162) - 2020 Q1 - 季度财报
2020-04-27 16:00
Financial Performance - The company's revenue for Q1 2020 was ¥121,471,485.59, a decrease of 35.36% compared to ¥187,927,447.05 in the same period last year[7] - The net profit attributable to shareholders was -¥19,076,892.88, representing a decline of 153.69% from -¥7,519,849.53 year-on-year[7] - The net cash flow from operating activities was -¥67,104,046.16, a significant drop of 558.94% compared to -¥10,183,642.94 in the previous year[7] - The company reported a weighted average return on equity of -1.97%, a decline of 1.16% compared to -0.81% in the previous year[7] - The net loss for the period was CNY 23,120,000, reflecting a significant decrease in profitability compared to the previous year[38] - The company's total profit for Q1 2020 was -¥20,389,800.85, compared to -¥7,253,694.69 in the same period last year[39] - The operating profit for Q1 2020 was -¥20,192,667.88, compared to -¥6,891,558.15 in the previous year, indicating a significant decline[39] - The net profit for Q1 2020 was a loss of ¥20,710,620.47, compared to a loss of ¥8,147,129.65 in the same period last year, representing an increase in loss of approximately 154.5%[40] Cash Flow - The net cash flow from operating activities was -67,104,046.16 CNY, compared to -10,183,642.94 CNY in the previous period, indicating a significant decline in operational cash flow[47] - Cash inflow from investment activities totaled 222,246,031.37 CNY, up from 142,473,342.89 CNY, while cash outflow for investments increased to 239,450,721.77 CNY from 182,550,456.52 CNY, resulting in a net cash flow from investment activities of -17,204,690.40 CNY, an improvement from -40,077,113.63 CNY[47] - The net cash flow from financing activities was 23,009,896.16 CNY, a recovery from -6,180,546.27 CNY in the previous period, driven by increased borrowings of 213,579,987.96 CNY compared to 168,580,000.00 CNY[48] - The cash outflow for operating activities was 115,045,443.15 CNY, a decrease from 122,781,237.85 CNY, leading to a net cash flow of 23,315,862.00 CNY, down from 53,961,626.66 CNY[50] - The company recorded a significant increase in cash received from investment recoveries, totaling 155,000,000.00 CNY, compared to 99,500,000.00 CNY in the previous period[51] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,308,120,869.63, down 1.38% from ¥2,340,351,166.84 at the end of the previous year[7] - The total assets as of March 31, 2020, were CNY 2.31 billion, a decrease from CNY 2.34 billion at the end of 2019[30] - Total liabilities amounted to CNY 1,347,767,676.46, with current liabilities at CNY 936,884,061.63 and non-current liabilities at CNY 410,883,614.83[55] - The company's equity attributable to shareholders was CNY 977,740,693.11, while total equity stood at CNY 992,583,490.38[55] - The company's total assets as of March 31, 2020, amounted to CNY 2,719,141,874.69, compared to CNY 2,640,592,119.01 at the end of 2019[34] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,959[11] - The basic and diluted earnings per share for Q1 2020 were both -¥0.0223, compared to -¥0.0088 in the previous year[40] Government Support - The company received government subsidies amounting to ¥1,504,361.73, primarily from the Shanghai government for business support[8] Other Financial Metrics - The company incurred financial expenses of ¥6,017,964.58 in Q1 2020, slightly down from ¥6,391,126.36 in the previous year[42] - The research and development expenses for Q1 2020 were ¥587,332.77, compared to ¥576,788.66 in the previous year, showing a slight increase[42] - The company reported other income of ¥499,603.40 in Q1 2020, compared to ¥434,032.00 in the previous year[42] Changes in Accounting Standards - The implementation of new revenue and leasing standards began in 2020, which may impact future financial reporting[59] Audit Status - The company has not yet audited its first-quarter report, which may affect the reliability of the financial data presented[60]
悦心健康(002162) - 2019 Q4 - 年度财报
2020-03-27 16:00
Financial Performance - The company's operating revenue for 2019 was CNY 1,166,237,543.76, representing a 19.26% increase compared to CNY 977,878,550.06 in 2018[18]. - The net profit attributable to shareholders for 2019 was CNY 37,872,539.05, a significant increase of 55.55% from CNY 24,347,051.63 in 2018[18]. - The net profit after deducting non-recurring gains and losses reached CNY 18,895,063.89, a remarkable increase of 7,567.29% compared to CNY 246,437.39 in 2018[18]. - The basic earnings per share for 2019 was CNY 0.0444, up 55.79% from CNY 0.0285 in 2018[18]. - The total assets at the end of 2019 amounted to CNY 2,340,351,166.84, reflecting a 2.82% increase from CNY 2,276,109,018.65 at the end of 2018[18]. - The net assets attributable to shareholders increased by 4.77% to CNY 977,740,693.11 at the end of 2019, compared to CNY 933,236,725.42 at the end of 2018[18]. - The net cash flow from operating activities for 2019 was CNY 132,140,708.26, showing a slight decrease of 2.48% from CNY 135,507,796.69 in 2018[18]. - The weighted average return on equity for 2019 was 3.98%, an increase of 1.24 percentage points from 2.74% in 2018[18]. - The company reported a government subsidy of 9,621,384.82 CNY in 2019, which was a decrease from 12,603,041.74 CNY in 2018[24]. - The company achieved total revenue of 1.166 billion yuan in 2019, an increase of 19.26% year-on-year, and a net profit attributable to shareholders of 37.87 million yuan, up 55.55% from the previous year[41]. Revenue Segmentation - The fashion health building materials segment accounted for 84.70% of total revenue, with a year-on-year growth of 12.23%, while the medical elderly care service segment saw a significant increase of 216.56%[41]. - The company's tile business revenue reached 977 million yuan in 2019, marking a historical high with a growth of 13.49%[43]. - The medical segment saw a significant growth of 216.56%, with revenue increasing to ¥95,775,632.46 from ¥30,255,247.98 in the previous year[71]. - Domestic sales accounted for 97.35% of total revenue, amounting to ¥1,135,307,508.05, up 19.87% from ¥947,089,660.26 in 2018[73]. - The sales volume of tiles increased by 19.87% to 1,825.11 million square meters in 2019, compared to 1,522.54 million square meters in 2018[76]. Product Development and Innovation - The company launched a new large-format imitation marble tile measuring 1200*2400mm during the reporting period, enhancing its product offerings in the high-end ceramic market[28]. - The company has developed a new series of water-based inorganic coatings in 20 color options to meet customer demands in the health materials segment[29]. - The company launched new high-end products, including a granite series of polished tiles and a large slab series, to meet market demand and enhance product innovation[47]. - The company initiated 7 new R&D projects, completing 4 by year-end, with all completed projects meeting expected technical indicators[91]. - R&D investment increased by 14.32% year-over-year to approximately ¥42.97 million, representing 3.68% of operating revenue[91]. Market Expansion and Strategy - The company is focusing on expanding its healthcare services, particularly in comprehensive hospitals and specialized clinics, through both organic growth and acquisitions[29]. - The company plans to enhance its market position by focusing on quality, brand, and service rather than solely on price competition[118]. - The company plans to strategically transform towards the health and wellness industry while consolidating its current building materials business, focusing on a brand named "Yuexin" for health services[125]. - The company is collaborating with the government on a senior care project in Shanghai, which will provide high-quality services for the elderly, set to be operational in 2020[129]. - The company is developing a "Yuexin Health Science and Technology Innovation Park" on approximately 560 acres of industrial land in Shanghai, focusing on smart health medical research and development[130]. Financial Management and Investments - The company has short-term borrowings of CNY 195,000,000 from the Industrial and Commercial Bank of China, secured by real estate valued at CNY 79,860,730.96[103]. - The company has long-term borrowings of CNY 266,250,000 from Shanghai Rural Commercial Bank, secured by real estate valued at CNY 110,677,264.58[104]. - The company reported a total of CNY 948,300,000 in purchases and CNY 960,400,000 in sales of financial assets during the period[102]. - The company’s total investment amount for the reporting period was CNY 90,800,000, representing a 7.38% increase compared to the previous year's investment of CNY 84,558,160[105]. - The company has committed to providing financial support to address short-term liquidity issues, including funding and guarantees[144]. Compliance and Governance - The company emphasizes the importance of adhering to relevant disclosure requirements as per the Shenzhen Stock Exchange guidelines[4]. - The company has maintained compliance with its commitments regarding avoiding competition with its subsidiaries[146]. - The company has conducted multiple investor relations activities throughout the year, including site visits by institutions[136]. - The company has adhered to regulatory requirements in its profit distribution plan implementation[139]. - The company has not reported any significant accounting errors or restatements during the reporting period[157]. Social Responsibility and Environmental Impact - The company has prepared and disclosed the 2019 Social Responsibility Report, emphasizing its commitment to social responsibility[193]. - Environmental protection measures include compliance with the "Ceramic Industry Pollutant Emission Standards" (GB25464-2010), achieving zero discharge for treated wastewater[195][200]. - The company has obtained a pollution discharge permit valid from October 17, 2019, to October 16, 2022[197]. - Emission standards for major pollutants such as SO2 and NOX were met, with no exceedances reported[199]. - The company implements a comprehensive management system for quality, environment, energy, and occupational health safety, with annual certifications[196].
悦心健康(002162) - 2019 Q3 - 季度财报
2019-10-29 16:00
Financial Performance - Operating revenue for the reporting period was CNY 347,549,996.90, representing a year-on-year increase of 25.49%[7] - Net profit attributable to shareholders of the listed company was CNY 19,699,893.73, up 72.61% year-on-year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 19,150,329.22, an increase of 74.91% compared to the same period last year[7] - Basic earnings per share were CNY 0.0231, reflecting a growth of 73.68% year-on-year[7] - The net profit for the first nine months of 2019 was RMB 34,217,985.46, reflecting a 73.06% increase from RMB 19,772,378.54 in the same period of 2018[20] - The net profit for Q3 2019 was CNY 19,446,690.42, representing a 80.5% increase from CNY 10,803,280.41 in Q3 2018[47] - The total profit for Q3 2019 was ¥11,949,992.52, which is a 118.1% increase from ¥5,461,908.56 in Q3 2018[50] - Net profit for the current period is ¥34,135,200.71, representing a 67.93% increase compared to ¥20,325,516.40 in the previous period[58] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,274,763,597.85, a decrease of 0.06% compared to the end of the previous year[7] - The company's total liabilities decreased to CNY 1,286,228,524.61 from CNY 1,325,740,926.15, a reduction of about 3%[38] - The total assets of the company as of Q3 2019 amounted to CNY 2,505,841,821.56, compared to CNY 2,356,838,764.21 at the end of Q3 2018, reflecting a growth of 6.3%[44] - The total liabilities increased to CNY 1,106,923,921.17, up from CNY 998,667,308.33, marking an increase of 10.9% year-on-year[44] - The company’s short-term liabilities due within one year decreased by 64.57% to RMB 16,666,725.00, primarily due to repayments of financing lease obligations[16] - The company reported a total asset value of CNY 2,276,109,018.65, with total liabilities amounting to CNY 1,173,325,038.68[70] - The company’s total liabilities included short-term borrowings of CNY 492,450,000.00 and long-term borrowings of CNY 282,916,812.50[71] Cash Flow - The net cash flow from operating activities was CNY 29,015,240.57, a decrease of 2.33% compared to the previous year[7] - The net cash flow from investing activities improved by 85.18% year-on-year, amounting to RMB -8,842,941.89, due to net inflows from financial products and asset disposals[24] - The company’s cash flow from financing activities decreased by 410.45% year-on-year to RMB -149,888,271.39, attributed to reduced bank borrowings and increased operational cash flow[24] - Cash flow from operating activities generated a net amount of ¥70,946,959.27, an increase from ¥55,497,380.16 in the previous period[62] - Cash flow from investing activities resulted in a net outflow of ¥8,842,941.89, compared to a net outflow of ¥59,650,198.16 in the previous period[63] - The net cash flow from financing activities was negative at CNY -60,039,971.81, compared to a positive CNY 4,699,312.56 in the same period last year[67] Shareholder Information - Net profit attributable to the parent company for Q3 2019 was RMB 19,699,893.73, a 72.61% increase compared to RMB 11,412,680.79 in Q3 2018[18] - The total number of ordinary shareholders at the end of the reporting period was 56,743[11] - The equity attributable to shareholders of the parent company increased to CNY 974,102,207.62 from CNY 933,236,725.42, reflecting an increase of approximately 4.4%[39] - The company reported a total equity of CNY 1,398,917,900.39, an increase from CNY 1,358,171,455.88 in the same quarter last year, representing a growth of 3.0%[44] Government Support and Other Income - The company received government subsidies totaling CNY 8,185,528.55 during the reporting period[8] - Investment income rose significantly by 428.50% year-on-year to RMB 1,887,896.42, driven by increased returns from investments in Xinshan Insurance Agency Co., Ltd.[18] - The company reported a significant decrease in interest income by 70.80% year-on-year to RMB 706,925.75, as previous structured financial product returns were reclassified[20] Expenses - The company's management expenses increased by 46.69% year-on-year to RMB 23,706,593.01, primarily due to higher rental and operational costs for newly acquired subsidiaries[18] - Operating costs for the same period were CNY 326,344,673.75, up 23.9% from CNY 263,228,277.27 year-on-year[46] - Research and development expenses for Q3 2019 were CNY 2,386,997.43, a decrease of 23.6% from CNY 3,120,536.03 in Q3 2018[46] - The company's financial expenses for Q3 2019 were ¥6,873,923.53, an increase of 29.0% from ¥5,327,429.32 in the same period last year[50]
悦心健康(002162) - 2019 Q2 - 季度财报
2019-08-23 16:00
Financial Performance - The company's operating revenue for the first half of 2019 was CNY 502,663,499.02, representing an increase of 18.72% compared to CNY 423,396,701.00 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 14,518,091.73, a significant increase of 73.67% from CNY 8,359,697.75 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 4,704,490.71, a turnaround from a loss of CNY 6,864,948.85 in the same period last year, marking a 168.53% improvement[18]. - The net cash flow from operating activities was CNY 41,931,718.70, up 62.59% from CNY 25,790,233.83 in the previous year[18]. - The total assets at the end of the reporting period were CNY 2,375,123,018.66, an increase of 4.35% from CNY 2,276,109,018.65 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were CNY 954,363,824.40, reflecting a growth of 2.26% from CNY 933,236,725.42 at the end of the previous year[18]. - The basic earnings per share increased to CNY 0.0170, up 73.47% from CNY 0.0098 in the same period last year[18]. - The company achieved a revenue of RMB 502.66 million in the reporting period, representing a year-on-year growth of 18.72%[54]. - The total operating profit for the first half of 2019 was CNY 30,906,695.68, an increase from CNY 19,164,518.30 in the same period of 2018, representing a growth of approximately 61.5%[167]. - The net profit for the first half of 2019 reached CNY 23,939,261.87, compared to CNY 15,108,946.05 in the first half of 2018, indicating a year-over-year increase of about 58.7%[167]. Investment and Expansion - The company has invested in multiple medical institutions, including the Xuzhou Medical University Yuxin Dental Hospital and the American Daystar Reproductive Center, expanding its healthcare services[28]. - The company aims to establish a chain of clinics in key regions such as the Yangtze River Delta and the Pearl River Delta, focusing on women's reproductive health services[27]. - The company completed the acquisition of 70% of Quanqiao Tongren Hospital in Q4 2018, enhancing its medical service segment's performance[43]. - The company plans to continue acquiring and integrating regional medical institutions to form a regional health group, with a focus on county-level hospitals and community health services[50]. - The company plans to develop the "Yuexin Health Science and Technology Industrial Park" focusing on "smart medical care and elderly care" in response to local government initiatives[53]. - The company is focusing on developing energy-saving and environmentally friendly technologies in response to stricter national environmental policies[82]. - The company plans to continue expanding in the health industry through external acquisitions[84]. Product Development - The company launched a new 1200*2400mm marble tile product during the reporting period, enhancing its product line in the building ceramics sector[25]. - The company has developed a new line of negative ion health materials, which have been certified as "green building products" and are gaining market recognition[27]. - The company has developed a series of functional health building materials, including the Smick negative ion health board, which achieved operating revenue of CNY 3.67 million in the first half of 2019[44]. - The fashion health building materials segment accounted for 83.32% of total revenue, while medical and elderly care services contributed 8.73%, and investment property leasing accounted for 7.95%[43]. Financial Strategy and Management - The company has implemented an integrated information system to improve operational efficiency and management capabilities[37]. - The company has a structured approach to managing guarantees, ensuring compliance with financial obligations[111]. - The company’s financial strategy includes leveraging rental income to offset operational costs[108]. - The company has ongoing warehouse leases with average annual rents of 797.89 thousand RMB and 761.67 thousand RMB for different properties[107]. - The company has engaged in multiple lease agreements with different parties, reflecting a diversified rental income strategy[108]. Risks and Challenges - The company faces risks related to energy conservation policies, raw material price fluctuations, and integration risks in the healthcare industry[5]. - The company is actively managing risks associated with its transition to the healthcare industry, including potential changes in national medical policies[85]. - The company faces risks related to rising raw material and energy prices, which could impact profitability[83]. Environmental Compliance - The company has implemented effective pollution control measures, including a newly built desulfurization and dust removal facility that has been operational since April 2018[116]. - The company has established an emergency response plan for environmental incidents, which has been reviewed and filed with the local environmental protection bureau[117]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, with emissions of major pollutants such as smoke dust and SO2 below the national standards[115]. - The company faced an environmental penalty of 100,000 RMB due to wastewater pollution, with a remediation project costing 1 million RMB completed by March 2019[97]. Shareholder Matters - The company did not distribute cash dividends or bonus shares during the reporting period[6]. - The company repurchased and canceled a total of 1,775,000 restricted shares, reducing the total share capital from 855,550,000 to 853,775,000 shares[126][128]. - The largest shareholder, CIMIC INDUSTRIAL INC., holds 46.83% of the shares, totaling 399,795,802 shares[135]. - The total number of shares held by the top ten unrestricted shareholders amounts to 501,000,000 shares[136]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[137]. Financial Reporting and Compliance - The financial report for the first half of 2019 has not been audited[149]. - The preparation of financial statements is based on actual transactions and events[200]. - The company ensures the accuracy of financial data in its reporting[200]. - The financial statements reflect the company's commitment to transparency and compliance[200].
悦心健康(002162) - 2019 Q1 - 季度财报
2019-04-26 16:00
Financial Performance - The company's revenue for Q1 2019 was ¥187,927,447.05, representing a 28.92% increase compared to ¥145,774,417.64 in the same period last year[8] - The net profit attributable to shareholders was -¥7,519,849.53, an improvement of 37.59% from -¥12,049,923.61 year-over-year[8] - The basic earnings per share were -¥0.0088, a 37.59% improvement from -¥0.0141 in the same period last year[8] - The company's operating revenue for Q1 2019 was ¥187,927,447.05, representing a year-on-year increase of ¥42,153,029.41 or 28.92%[19] - The net profit attributable to shareholders for Q1 2019 was -¥7,519,849.53, an improvement of ¥4,530,074.08 or 37.59% compared to the same period last year[19] - The company reported a significant increase in other income, which rose to ¥2,239,855.31, a year-on-year increase of 909.44%[19] - The company reported a net loss of ¥186,832,263.76, worsening from a loss of ¥179,312,414.23[36] - Net loss for Q1 2019 was CNY 8,147,129.65, compared to a net loss of CNY 13,047,980.45 in the previous period, indicating an improvement[44] Cash Flow - The net cash flow from operating activities improved by 52.15%, reaching -¥10,183,642.94 compared to -¥21,282,637.90 in the previous year[8] - Operating cash flow for the period was negative at -10,183,642.94, an improvement from -21,282,637.90 in the previous year[52] - The company reported cash inflows from operating activities of 206,810,584.88, compared to 175,461,911.90 in the previous year, reflecting a growth of approximately 17.9%[52] - The net cash flow from operating activities for Q1 2019 was CNY 53,961,626.66, an increase of 115.5% compared to CNY 25,051,919.38 in Q1 2018[56] - Investment activities resulted in a net cash outflow of -40,077,113.63, worsening from -17,638,563.61 in the previous year[53] - Financing activities generated a net cash outflow of -6,180,546.27, compared to a net inflow of 10,091,196.81 in the previous year, indicating a shift in financing strategy[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,277,295,490.22, a slight increase of 0.05% from ¥2,276,109,018.65 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 0.81% to ¥925,684,211.81 from ¥933,236,725.42 at the end of the previous year[8] - Total current assets increased to ¥733,846,143.36 from ¥723,072,045.92, representing a growth of 2.4%[34] - Total non-current assets decreased to ¥1,543,449,346.86 from ¥1,553,036,972.73, a decline of 0.6%[34] - Total liabilities increased to ¥1,335,128,967.50 from ¥1,325,740,926.15, an increase of 0.3%[35] - Total liabilities amounted to CNY 1,035,874,047.84 from CNY 998,667,308.33 in the previous period[41] - Total equity decreased to ¥942,166,522.72 from ¥950,368,092.50, a decline of 0.9%[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,382[12] - The largest shareholder, CIMIC Industrial Inc., held 46.83% of the shares, amounting to 399,795,802 shares[12] Operational Metrics - The company experienced a 263.07% increase in investment income, reaching ¥2,244,156.20 in Q1 2019[19] - The company's accounts receivable decreased by 67.45%, from ¥10,598,477.21 to ¥3,449,511.57[18] - The prepayments increased by 92.30%, from ¥11,914,934.27 to ¥22,912,858.57, primarily due to increased procurement payments[18] - The company’s management expenses rose by 45.55%, totaling ¥19,610,194.78, attributed to the acquisition of a subsidiary and increased operational costs[20] - The fair value change income for the period was reported at ¥362,785.62, reflecting gains from unredeemed financial products[20] Government Support - The company received government subsidies totaling ¥2,239,855.31, primarily from the Minhang District government in Shanghai[9] Other Financial Metrics - Research and development expenses for Q1 2019 were CNY 1,666,826.12, down from CNY 2,061,746.99 in the previous period[42] - The total amount of prepayments increased to CNY 152,010,502.83 from CNY 114,228,807.26 in the previous period[40] - The company has a total of CNY 121,609,299.52 in other comprehensive income[64] - The total amount of deferred tax assets is CNY 3,966,317.16[64]
悦心健康(002162) - 2018 Q4 - 年度财报
2019-02-27 16:00
Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year increase of 15%[12] - The net profit attributable to shareholders was RMB 150 million, which is a 10% increase compared to the previous year[12] - The company's operating revenue for 2018 was ¥977,878,550.06, an increase of 8.63% compared to ¥900,219,675.70 in 2017[15] - Net profit attributable to shareholders for 2018 was ¥24,347,051.63, representing a growth of 20.70% from ¥20,172,331.05 in 2017[15] - The net cash flow from operating activities increased by 22.93% to ¥135,507,796.69 in 2018 from ¥110,234,818.43 in 2017[15] - The total assets of the company reached RMB 2.5 billion, reflecting a 12% growth from the previous year[12] - The company's net profit for the year was ¥22,402,600, with a significant difference of ¥11,110,520 between net profit and cash flow from operating activities[78] User Growth and Market Expansion - User data indicated a growth in active users by 20%, reaching a total of 500,000 users by the end of 2018[12] - The company plans to expand its market presence by entering three new provinces in 2019, aiming for a 25% increase in market share[12] - The company aims to enhance its market presence in the ecological health building materials sector, focusing on market expansion and production based on demand[24] - The company is exploring potential acquisitions to enhance its product portfolio and market reach[193] - The company is expanding its market presence, targeting an increase in market share by 5% in the next year[193] Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on new healthcare technologies[12] - The company invested CNY 37.59 million in R&D, reflecting a 3.44% increase from the previous year[53] - Research and development investments have increased by 25%, focusing on innovative healthcare solutions[193] - The company completed a total of 10 R&D projects by the end of 2018, including 7 new projects initiated during the year[72] Strategic Partnerships and Acquisitions - The company is exploring strategic partnerships to enhance its service offerings in the healthcare sector[12] - The company acquired 70% equity of Quanjiao Tongren Hospital, marking a step towards establishing a regional health complex[37] - The company plans to deepen cooperation with regional medical universities and continue acquiring or integrating local medical institutions[35] - The company has acquired 70% of Anhui Quanjiao Tongren Hospital Co., Ltd. and plans to continue expanding in the health industry through mergers and acquisitions[109] Operational Efficiency and Cost Management - The company aims to improve operational efficiency, targeting a 10% reduction in costs through process optimization[193] - The company has maintained a stable debt-to-equity ratio of 0.5, indicating a balanced financial structure[12] - The company’s profit margin improved, with a total profit of CNY 30.53 million, up 25.23% from the previous year[34] Environmental and Social Responsibility - The company has implemented an integrated ultra-low emission facility since April 2018, achieving compliance with national emission standards[158] - The company has established an emergency response plan for environmental incidents, approved by the Fengcheng Environmental Protection Bureau[160] - The company has prepared and disclosed the 2018 Social Responsibility Report[156] - Jiangxi Smick's total emissions for smoke dust were 135.99 tons, well below the annual limit of 300 tons[158] Shareholder and Management Information - The total number of shareholders at the end of the reporting period is 46[173] - CIMIC Industrial Inc. holds 46.73% of the shares, totaling 399,795,802 shares, with 264,080,000 shares pledged[175] - The actual controller of the company is Li Cixiong, who has been the chairman since 1993 and the president since July 25, 2018[178] - The company has not undergone any changes in its actual controller during the reporting period[178] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[193] - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on health and wellness products[193] - A new strategic partnership has been established, expected to generate an additional 150 million RMB in revenue over the next two years[193]